​

Assertio (ASRT) Revenue & Revenue Breakdown

OverviewForecastOwnershipFinancialsChartTranscripts

Assertio Revenue Highlights

Latest Revenue (Y)

$152.07M

Latest Revenue (Q)

$29.20M

Main Segment (Y)

Product

Main Geography (Y)

CANADA

Assertio Revenue by Period

Assertio Revenue by Year

DateRevenueChange
2023-12-31$152.07M-2.67%
2022-12-31$156.23M40.73%
2021-12-31$111.01M4.46%
2020-12-31$106.28M-53.69%
2019-12-31$229.50M-26.39%
2018-12-31$311.77M-18.11%
2017-12-31$380.72M-16.49%
2016-12-31$455.90M33.02%
2015-12-31$342.74M-12.20%
2014-12-31$390.36M190.87%
2013-12-31$134.21M47.78%
2012-12-31$90.82M-31.70%
2011-12-31$132.97M64.64%
2010-12-31$80.76M39.90%
2009-12-31$57.73M65.69%
2008-12-31$34.84M-46.87%
2007-12-31$65.58M586.63%
2006-12-31$9.55M116.81%
2005-12-31$4.41M2074.73%
2004-12-31$202.57K-79.37%
2003-12-31$981.99K-40.89%
2002-12-31$1.66M-54.78%
2001-12-31$3.67M106.81%
2000-12-31$1.78M1440.16%
1999-12-31$115.33K-85.58%
1998-12-31$800.00K33.33%
1997-12-31$600.00K100.00%
1996-12-31$300.00K-

Assertio generated $152.07M in revenue during NA 2023, up -2.67% compared to the previous quarter, and up 48.78% compared to the same period a year ago.

Assertio Revenue by Quarter

DateRevenueChange
2024-09-30$29.20M-6.17%
2024-06-30$31.13M-4.07%
2024-03-31$32.45M-1.63%
2023-12-31$32.98M-7.42%
2023-09-30$35.63M-13.09%
2023-06-30$40.99M-3.47%
2023-03-31$42.47M-15.66%
2022-12-31$50.35M47.18%
2022-09-30$34.21M-2.62%
2022-06-30$35.13M-3.85%
2022-03-31$36.54M9.62%
2021-12-31$33.33M30.85%
2021-09-30$25.47M0.39%
2021-06-30$25.37M-5.46%
2021-03-31$26.84M-11.06%
2020-12-31$30.18M-12.70%
2020-09-30$34.56M67.65%
2020-06-30$20.62M-1.43%
2020-03-31$20.92M-64.68%
2019-12-31$59.23M7.40%
2019-09-30$55.15M-3.59%
2019-06-30$57.20M-1.25%
2019-03-31$57.93M35.99%
2018-12-31$42.60M-45.03%
2018-09-30$77.49M22.47%
2018-06-30$63.27M-50.72%
2018-03-31$128.40M36.01%
2017-12-31$94.41M-1.05%
2017-09-30$95.41M-5.02%
2017-06-30$100.46M11.07%
2017-03-31$90.45M-27.01%
2016-12-31$123.91M12.11%
2016-09-30$110.52M-5.28%
2016-06-30$116.68M11.36%
2016-03-31$104.78M-5.75%
2015-12-31$111.17M6.02%
2015-09-30$104.86M10.95%
2015-06-30$94.50M193.46%
2015-03-31$32.20M-83.45%
2014-12-31$194.60M277.98%
2014-09-30$51.48M-23.99%
2014-06-30$67.73M-11.51%
2014-03-31$76.54M88.49%
2013-12-31$40.61M8.41%
2013-09-30$37.46M25.02%
2013-06-30$29.96M14.48%
2013-03-31$26.17M-1.56%
2012-12-31$26.59M-20.11%
2012-09-30$33.28M135.88%
2012-06-30$14.11M-16.19%
2012-03-31$16.84M38.77%
2011-12-31$12.13M-26.57%
2011-09-30$16.52M-22.13%
2011-06-30$21.22M-74.47%
2011-03-31$83.10M298.39%
2010-12-31$20.86M3.64%
2010-09-30$20.13M-17.58%
2010-06-30$24.42M58.98%
2010-03-31$15.36M16.06%
2009-12-31$13.23M-42.50%
2009-09-30$23.01M98.26%
2009-06-30$11.61M17.59%
2009-03-31$9.87M13.28%
2008-12-31$8.71M-38.24%
2008-09-30$14.11M123.45%
2008-06-30$6.32M10.77%
2008-03-31$5.70M7.87%
2007-12-31$5.29M-

Assertio generated $29.20M in revenue during Q3 2024, up -6.17% compared to the previous quarter, and up 71.24% compared to the same period a year ago.

Assertio Revenue Breakdown

Assertio Revenue Breakdown by Product

Annual Revenue by Product

Product/ServiceDec 22Dec 21Dec 20
Zipsor$3.36M$10.19M$13.29M
SPRIX Nasal Spray$9.11M$8.68M$11.08M
Royalties And Milestones$2.40M$2.58M$1.52M
Product, Other$4.67M$5.03M-
Product$155.12M$109.42M$93.50M
Otrexup$11.15M--
Other Revenue$-1.29M$-985.00K-
INDOCIN Products$100.34M$60.56M$31.68M
C A M B I A$24.72M$24.97M$28.35M
Product and Service, Other-$-985.00K$9.10M
Commercialization Agreement--$11.26M

Assertio's latest annual revenue breakdown by segment (product or service), as of Dec 22: Product (50.11%), INDOCIN Products (32.41%), C A M B I A (7.98%), Otrexup (3.60%), SPRIX Nasal Spray (2.94%), Product, Other (1.51%), Zipsor (1.09%), Royalties And Milestones (0.78%), and Other Revenue (-0.42%).

Quarterly Revenue by Product

Product/ServiceSep 24Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21Dec 20Sep 20Jun 20
SPRIX Nasal Spray$2.00M$2.54M$2.37M$1.89M$2.67M$2.46M$1.77M$1.76M$2.94M$1.70M$3.83M$5.64M$1.60M--
Royalties And Milestones$499.00K$490.00K$723.00K$697.00K$487.00K$473.00K$451.00K$992.00K$1.19M$416.00K$542.00K$434.00K$361.00K$299.00K$452.00K
Product, Other$214.00K$12.00K$605.00K$796.00K$786.00K$884.00K$1.64M$1.31M-------
Product$28.70M$35.14M$40.08M$41.77M$49.86M$34.28M$35.43M$35.55M$32.15M$26.00M$24.83M$26.41M$29.82M$34.27M$20.16M
Otrexup$1.80M--------------
INDOCIN Products$5.67M$17.95M$28.07M$30.35M$34.27M$21.87M$21.36M$18.34M$13.07M$14.60M$12.48M$13.77M$5.43M--
CAMBIA$1.36M$1.99M$1.80M$2.26M$5.81M$5.47M$6.13M$6.46M$7.45M------
Otrexup Acquisition-$2.81M$3.59M$2.82M$3.00M$3.08M---------
Product and Service, Other--$185.00K$-540.00K$-750.00K-$-9.00K$-941.00K$105.00K$1.43M$2.63M$4.01M---
Zipsor-$597.00K$1.00M$1.15M$660.00K$259.00K$2.23M$3.38M$2.58M$2.22M$4.03M$3.40M$3.54M--
C A M B I A----$7.26M$7.34M$6.85M$7.78M-------
Commercialization Agreement---------------
Commercialization Rights And Facilitation Services---------------
SOLUMATRIX Products--------------$836.00K
Gralise--------------$-116.00K
Janssen Nucynta--------------$577.00K
OXAYDO--------------$517.00K

Assertio's latest quarterly revenue breakdown by segment (product or service), as of Sep 24: Product (71.32%), INDOCIN Products (14.09%), SPRIX Nasal Spray (4.96%), Otrexup (4.47%), CAMBIA (3.39%), Royalties And Milestones (1.24%), and Product, Other (0.53%).

Assertio Revenue Breakdown by Country

Annual Revenue by Country

CountryDec 22Dec 21Dec 20
CANADA$1.90M$2.50M$1.50M

Assertio's latest annual revenue breakdown by geography, as of Dec 22: CANADA (100.00%).

Quarterly Revenue by Country

CountrySep 24Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 20Sep 20
CANADA$500.00K$500.00K$400.00K$500.00K$400.00K$500.00K$500.00K$500.00K$300.00K$300.00K

Assertio's latest quarterly revenue breakdown by geography, as of Sep 24: CANADA (100.00%).

Assertio Peer Comparison by Revenue

TickerCompanyLast Year RevenueLast Quarter Revenue
RDYDr. Reddy's Laboratories$279.16B-
AMRXAmneal Pharmaceuticals$2.39B$702.47M
NBIXNeurocrine Biosciences$1.89B$622.10M
ALKSAlkermes$1.66B$378.14M
PCRXPacira BioSciences$674.98M$168.57M
AMPHAmphastar Pharmaceuticals$593.24M$188.82M
COLLCollegium Pharmaceutical$566.77M$159.30M
ANIPANI Pharmaceuticals$486.82M$148.33M
ITCIIntra-Cellular Therapies$462.18M$175.38M
IRWDIronwood Pharmaceuticals$442.74M$91.59M
EOLSEvolus$199.72M$60.16M
ASRTAssertio$152.07M$29.20M
LFCRLifecore Biomedical$128.26M$32.56M
ESPREsperion Therapeutics$116.33M$51.63M
ALVOAlvotech$91.43M$12.43M

ASRT Revenue FAQ

What is Assertio’s yearly revenue?

Assertio's yearly revenue for 2023 was $152.07M, representing a decrease of -2.67% compared to 2022. The company's yearly revenue for 2022 was $156.23M, representing an increase of 40.73% compared to 2021. ASRT's yearly revenue for 2021 was $111.01M, representing an increase of 4.46% compared to 2020.

What is Assertio’s quarterly revenue?

Assertio's quarterly revenue for Q3 2024 was $29.2M, a -6.17% decrease from the previous quarter (Q2 2024), and a -18.03% decrease year-over-year (Q3 2023). The company's quarterly revenue for Q2 2024 was $31.13M, a -4.07% decrease from the previous quarter (Q1 2024), and a -24.07% decrease year-over-year (Q2 2023). ASRT's quarterly revenue for Q1 2024 was $32.45M, a -1.63% decrease from the previous quarter (Q4 2023), and a -23.59% decrease year-over-year (Q1 2023).

What is Assertio’s revenue growth rate?

Assertio's revenue growth rate for the last 3 years (2021-2023) was 36.98%, and for the last 5 years (2019-2023) was -33.74%.

What are Assertio’s revenue streams?

Assertio's revenue streams in c 22 are Zipsor, SPRIX Nasal Spray, Royalties And Milestones, Product, Other, Product, Otrexup, Other Revenue, INDOCIN Products, and C A M B I A. Zipsor generated $3.36M in revenue, accounting 1.09% of the company's total revenue, down -66.97% year-over-year. SPRIX Nasal Spray generated $9.11M in revenue, accounting 2.94% of the company's total revenue, up 5.00% year-over-year. Royalties And Milestones generated $2.4M in revenue, accounting 0.78% of the company's total revenue, down -6.82% year-over-year. Product, Other generated $4.67M in revenue, accounting 1.51% of the company's total revenue, down -7.10% year-over-year. Product generated $155.12M in revenue, accounting 50.11% of the company's total revenue, up 41.77% year-over-year. Otrexup generated $11.15M in revenue, accounting 3.60% of the company's total revenue Other Revenue generated $-1.29M in revenue, accounting -0.42% of the company's total revenue, up 30.96% year-over-year. INDOCIN Products generated $100.34M in revenue, accounting 32.41% of the company's total revenue, up 65.69% year-over-year. C A M B I A generated $24.72M in revenue, accounting 7.98% of the company's total revenue, down -1.01% year-over-year.

What is Assertio’s main source of revenue?

For the fiscal year ending Dec 22, the largest source of revenue of Assertio was Product. This segment made a revenue of $155.12M, representing 50.11% of the company's total revenue.